June 26, 2023
Re: Changes to the QTdrugs List and List of Drugs to Avoid in cLQTS
Dear CredibleMeds Registrants:
AZCERT's Scientific Review Committee has found substantial evidence that Pacritinib (anticancer), Vernakalant (antiarrhythmic) and Fexinidazole (antiparasitic) are associated with the development of QT prolongation but lack convincing evidence of torsades de pointes (TdP). Therefore, these drugs have been added to the Possible Risk of TdP category (PR) and the List of Drugs to Avoid in patients with Congenital Long QT Syndrome (DTA List).
As demonstrated by these revisions, the QTdrugs list is dynamic and changes regularly. To perform a quick search of the Lists we recommend using the CredibleMeds website and the smartphone app (Apple or Android).
We hope you will consider making a contribution to support AZCERT's work to maintain the QTdrugs List and the CredibleMeds website. Your support makes it all possible. Click here to donate now.
Thank you for your continued support of CredibleMeds.